<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCD2685E0594242768C94E76E40E41E5C" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5736 IH: Penicillin Allergy Verification and Evaluation Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-10-10</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5736</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20251010">October 10, 2025</action-date><action-desc><sponsor name-id="G000568">Mr. Griffith</sponsor> (for himself, <cosponsor name-id="B001287">Mr. Bera</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="S001216">Ms. Schrier</cosponsor>, <cosponsor name-id="D000617">Ms. DelBene</cosponsor>, <cosponsor name-id="O000177">Mr. Onder</cosponsor>, and <cosponsor name-id="A000148">Mr. Auchincloss</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to include penicillin allergy verification and evaluation as part of the initial preventive physical examination under the Medicare program.</official-title></form><legis-body id="HBADCEC44D6D74A4C9E415E2E71D928E3" style="OLC"><section id="H872E44362E6945E0A92C549D5D4D2D95" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Penicillin Allergy Verification and Evaluation Act</short-title></quote> or the <quote><short-title>PAVE Act</short-title></quote>.</text></section><section id="H2BCD6391026C498CB0743CD55D37E7C5"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following:</text><paragraph id="H8D96F6F353A74DB380ACF000C0FFF39F"><enum>(1)</enum><text>On September 28, 1928, Alexander Fleming, a Scottish bacteriologist, discovered penicillin, forever changing healthcare by identifying an effective way to treat a wide range of infections which opened the door for numerous successful medical treatments.</text></paragraph><paragraph id="HB8BF4453863C4B06BD5C17DCB7F543C4"><enum>(2)</enum><text>Millions of patients believe they are allergic to penicillin, but information cited by the Centers for Disease Control and Prevention and recent medical journal articles in the Journal of the American Medical Association and the Journal of Allergy and Clinical Immunology, shows that more than 90 percent of patients who have a self-reported penicillin allergy in their electronic medical record can safely take penicillin after verification testing.</text></paragraph><paragraph id="H9510DDC791AA4AA986FCC3193319D58C"><enum>(3)</enum><text>A 2020 medical research review found, penicillin allergy is estimated to affect approximately 10 percent of the population, and 15 percent of hospitalized patients are labeled with a penicillin allergy.</text></paragraph><paragraph id="H389B4E4BDECB4DB89B7E74082B7A9430"><enum>(4)</enum><text>Penicillin allergy label is associated with poor patient outcomes including increased hospital length of stay, increased perioperative infections, and overall increased mortality according to the New England Journal of Medicine.</text></paragraph><paragraph id="H8B6DA2489EE742D8A1B0BAFF6E568DCF"><enum>(5)</enum><text>A 2018 paper in the Journal of Allergy and Clinical Immunology indicates that penicillin allergy evaluation by any means has been shown to be a cost-saving intervention.</text></paragraph><paragraph id="HF034E250AA9246DE821073C864DA0C48"><enum>(6)</enum><text>Delabeling penicillin allergy is an important component of antibiotic stewardship and is endorsed by many professional organizations and public health bodies, including the American Academy of Allergy, Asthma &amp; Immunology.</text></paragraph><paragraph id="H852FC55FFB91453588072A72FB11FE7A"><enum>(7)</enum><text>A 2023 study of adults 65 and older with a penicillin allergy label published in the Annals of Allergy, Asthma &amp; Immunology found that 97 percent were disproved after verification testing.</text></paragraph></section><section id="H1483CD32D12F4573BB5F80F975B576CE"><enum>3.</enum><header>Penicillin allergy verification and evaluation for seniors</header><subsection id="H591BC8C9FFA24FA982AB1488B8BD7EB4"><enum>(a)</enum><header>Initial preventive physical examination</header><text>Section 1861(ww) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(ww)</external-xref>) is amended—</text><paragraph id="H9688B4A665EC4EDFBC976B631B59F54C"><enum>(1)</enum><text>In paragraph (1)—</text><subparagraph id="HB4753140168240D88E5307FFFDC92DE3"><enum>(A)</enum><text>by inserting <quote>penicillin allergy verification and evaluation (as defined in paragraph (5)),</quote> after <quote>(as defined in paragraph (4)),</quote>;</text></subparagraph></paragraph><paragraph id="HE648BF3BBED645AF89C2C20D9C61B7BC"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="H7CD548EED26C43038B5E2A277430157D"><enum>(A)</enum><text>by redesignating subparagraph (O) as subparagraph (P); and</text></subparagraph><subparagraph id="H6DFBDC9F83B24140AD2A9D2F92582CD7"><enum>(B)</enum><text>by inserting after subparagraph (N) the following new subparagraph:</text><quoted-block id="HAC1A5616378546A8B791DFE3AAE3701F" style="OLC"><subparagraph id="HC3C11268E12747D5A0726720D613A081"><enum>(O)</enum><text>Penicillin allergy verification and evaluation.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HC214756245BB40B5BCBD3820355198F5"><enum>(3)</enum><text>by adding at the end the following new paragraph:</text><quoted-block id="H3FAE4C71077C4EBFB95C645AAE8E06A8" style="OLC"><paragraph id="H495FE4326DC94F7293016F5E81063076"><enum>(5)</enum><text>For purposes of paragraph (1), the term <quote>penicillin allergy verification and evaluation</quote> means—</text><subparagraph id="H96E5123D1AC5435EA82FB4C0BE55D5DC"><enum>(A)</enum><text>identification of individuals reporting a history of penicillin allergy;</text></subparagraph><subparagraph id="HE2EE45B8260C473AA93B23CE20C69E79"><enum>(B)</enum><text>consideration of whether the reported reaction history is consistent with an allergy or hypersensitivity reaction or can be reevaluated;</text></subparagraph><subparagraph id="HC45DD6237C8444E6BC0545FA681CF7C7"><enum>(C)</enum><text>the provision of information on the adverse individual and public health impact of a penicillin allergy label; and</text></subparagraph><subparagraph id="HDF5CFC8543F9435F850FA4EC0AFDF172"><enum>(D)</enum><text>a referral to an allergy or immunology specialist, as appropriate.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H8C82FEEF0A16436B8ED784B3F37D62FA"><enum>(b)</enum><header>Annual wellness visit</header><text>Section 1861(hhh)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(hhh)(2)</external-xref>) is amended—</text><paragraph id="H3FA9C60117F748319E4B72B4A1EFABFD"><enum>(1)</enum><text>by redesignating subparagraph (I) as subparagraph (J); and</text></paragraph><paragraph id="H559FF7FC6B0143AFAF20F67F64CCBE1F"><enum>(2)</enum><text>by inserting after subparagraph (H) the following new subparagraph:</text><quoted-block id="HFF039EB3CD1E4DFBA621B24F58A8141E" style="OLC"><subparagraph id="HB653668B13FB47F28F68D5192DBFAC8B"><enum>(I)</enum><text>Penicillin allergy verification and evaluation (as defined in subsection (ww)(5)).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H179D5C213CB1447BB2BAA61E2BFCC1BE"><enum>(c)</enum><header>Rule of construction</header><text>Nothing in the amendments made by subsection (a) or (b) shall be construed to prohibit separate payment for structured penicillin allergy validation and evaluation services furnished to an individual on the same day as an initial preventive physical examination or an annual wellness visit.</text></subsection><subsection id="HA3A3A2F3304D4443B67E2AAE22B6A01E"><enum>(d)</enum><header>Effective date</header><text>The amendments made by this section shall apply to examinations and visits furnished on or after January 1, 2027.</text></subsection></section></legis-body></bill> 

